Ribociclib plus Endocrine Therapy in Early Breast Cancer
Dennis J. Slamon, Oleg Nikolaevich Lipatov, Zbigniew Ireneusz Nowecki et al. · New England Journal of Medicine · 2024
BACKGROUND: Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Whether this benefit in advanced breast cancer extends to early breast cancer is unclear. METHODS: In this international, open-label, randomized, phase 3 trial, we randomly assigned patients with HR-positive, HER2-negative early breast cancer in a 1:1 ratio to receive ribociclib (at a dose of 400 mg per day for 3 weeks, followed by 1 week off, for 3 years) plus a nonsteroidal aromatase inhibitor (NSAI; letrozole at a dose of 2.5 mg per day or anastrozole at a dose of 1 mg per day for ≥5 years) or an NSAI alone. Premenopausal women and men also received goserelin every 28 days. Eligible patients had anatomical stage II or III breast cancer. Here we report the results of a prespecified interim analysis of invasive disease-free survival, the primary end point; other efficacy and safety results are also reported. Invasive disease-free survival was evaluated with the use of the Kaplan-Meier method. The statistical comparison was made with the use of a stratified log-rank test, with a protocol-specified stopping boundary of a one-sided P-value threshold of 0.0128 for superior efficacy. RESULTS: As of the data-cutoff date for this prespecified interim analysis (January 11, 2023), a total of 426 patients had had invasive disease, recurrence, or death. A significant invasive disease-free survival benefit was seen with ribociclib plus an NSAI as compared with an NSAI alone. At 3 years, invasive disease-free survival was 90.4% with ribociclib plus an NSAI and 87.1% with an NSAI alone (hazard ratio for invasive disease, recurrence, or death, 0.75; 95% confidence interval, 0.62 to 0.91; P = 0.003). Secondary end points - distant disease-free survival and recurrence-free survival - also favored ribociclib plus an NSAI. The 3-year regimen of ribociclib at a 400-mg starting dose plus an NSAI was not associated with any new safety signals. CONCLUSIONS: Ribociclib plus an NSAI significantly improved invasive disease-free survival among patients with HR-positive, HER2-negative stage II or III early breast cancer. (Funded by Novartis; NATALEE ClinicalTrials.gov number, NCT03701334.).
Cited by 405 works. doi:10.1056/nejmoa2305488
Authors
- Dennis J. Slamon
- Oleg Nikolaevich Lipatov
- Zbigniew Ireneusz Nowecki
- Nicholas Patrick McAndrew
- Bożena Kukiełka-Budny
- Daniil Stroyakovskiy
- Denise Aysel Yardley
- Chiun‐Sheng Huang
- Peter Andreas Fasching
- John Paul Crown
- Aditya Bardia
- Stephen Chia
- Seock‐Ah Im
- Manuel Ruíz-Borrego
- Sherene Loi
- Binghe Xu
- Sara Alsterlind Hurvitz
- Carlos H. Barrios
- Michael Untch
- Rebecca Moroose
References
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
- Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3